Pathway vs pathway.
Side by side. Provider-reviewed.

TRT and BHRT are both provider-reviewed hormone optimization pathways anchored to the same standardized biomarker panel. TRT addresses male testosterone deficiency. BHRT addresses female estrogen, progesterone, and (where indicated) testosterone imbalance through perimenopause, menopause, or select premenopausal contexts. Candidacy, modality, and cadence differ — the operating principles are shared.

TRT introduces exogenous testosterone. Enclomiphene stimulates the body's own production by selectively blocking estrogen receptors at the hypothalamus, which prompts LH and FSH release. Both are provider-reviewed pathways; candidacy depends on fertility goals, baseline biomarkers, and the dominant clinical vector.

Both are PDE5 inhibitors with the same fundamental mechanism. Tadalafil acts longer and supports daily-dose continuity. Sildenafil acts faster with a shorter active window and is typically used on demand. Selection is provider-reviewed against cardiovascular history, current medications, lifestyle, and continuity preference.

Sermorelin and TRT target different axes. Sermorelin signals the pituitary to release growth hormone in physiologic pulses, supporting sleep architecture, recovery, and body composition. TRT addresses the gonadal axis directly. They are not interchangeable — and in select cases they are paired under provider review.

Both deliver NAD+ to the same end. IV achieves rapid systemic levels in a clinic setting. Subcutaneous injection trades onset speed for at-home continuity. Selection is provider-reviewed against the patient's goal, schedule, and tolerance.

Both deliver testosterone into the optimization range. Injectables produce a peak-and-trough curve and require less-frequent dosing. Topical creams produce a steadier daily curve but require careful application discipline and transfer precautions. Selection is provider-reviewed against lifestyle, partner exposure, and biomarker response.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Head-to-head metabolic data show tirzepatide producing larger average weight loss and larger A1C reductions, while semaglutide carries the longer cardiovascular outcome track record in defined populations. The right molecule is a provider-reviewed match against biomarkers, tolerance, history, and access.

Wegovy and Zepbound are the two FDA-approved weight-management brands of the GLP-1 class. Wegovy is semaglutide; Zepbound is tirzepatide. The molecule-level comparison is the same comparison as semaglutide vs tirzepatide — Wegovy is GLP-1 mono-agonism, Zepbound is dual GIP/GLP-1. Choice is provider-reviewed against biomarkers, tolerance, cardiovascular history, and access.

Ozempic and Mounjaro are the FDA-approved type-2 diabetes brands of the GLP-1 class. Ozempic is semaglutide; Mounjaro is tirzepatide. Mounjaro produces larger average A1C reduction and larger weight loss at tolerated dose; Ozempic carries the longer cardiovascular outcome track record. The right molecule is a provider-reviewed match.

Pellets and injections are both provider-reviewed delivery modalities for hormone optimization. Pellets release steadily over 3–6 months from a subcutaneous insertion. Injections deliver weekly (or split twice-weekly) doses the patient self-administers. The right modality is matched against biomarker behavior, dose-adjustment flexibility, lifestyle, and continuity preference.

oMeds and form-only online TRT services both prescribe testosterone — the difference is the system around the molecule. oMeds is synchronous-only (live video with a licensed provider in the patient's state), anchored to the standardized biomarker panel at baseline and on cadence, with continuity built into the membership. Form-only services typically rely on text or intake-form review without a synchronous visit or required biomarker baseline.

Daily low-dose tadalafil maintains a steady plasma level so timing is no longer a variable. On-demand higher-dose tadalafil is used episodically and timed to activity. Both are provider-reviewed against cardiovascular history, current medications, lifestyle, and continuity preference. The choice is a lifestyle and pharmacokinetic match — not a potency comparison.

TRT and HCG operate at different points in the hypothalamic-pituitary-gonadal axis. TRT replaces testosterone directly. HCG mimics LH at the testes to stimulate endogenous testosterone production and preserve testicular function. They are sometimes alternatives, sometimes paired — the choice is provider-reviewed against candidacy, fertility goals, and trajectory.

Clomiphene citrate is a mixture of two isomers — enclomiphene (the trans-isomer, primarily estrogen-receptor antagonist) and zuclomiphene (the cis-isomer, primarily estrogen-receptor agonist with a long half-life). Enclomiphene is the isolated trans-isomer. The isolation matters: zuclomiphene accumulates and contributes the bulk of mood-related side effects historically associated with clomiphene.

BHRT uses hormones (estradiol, progesterone, testosterone) that are molecularly identical to those produced endogenously. Conventional synthetic HRT historically used conjugated equine estrogens and synthetic progestins (e.g., medroxyprogesterone). The molecular distinction matters for metabolism, receptor profile, and the evidence base on cardiovascular and breast outcomes.

Transdermal estradiol delivers the same molecule but bypasses first-pass hepatic metabolism. That single difference reshapes the clotting, inflammation, triglyceride, and SHBG profile. For most BHRT candidates, transdermal is the modern provider-preferred default; oral retains specific use cases.

Oral micronized progesterone produces reliable systemic levels and is the established standard for endometrial protection in women with a uterus on estrogen therapy. Topical progesterone delivers inconsistent serum levels and is not considered adequate for endometrial protection in conventional clinical use.

Compounded GLP-1s are prepared by licensed compounding pharmacies and frequently allow dosing flexibility (microdose ramp, custom titration) at lower cost. Branded GLP-1s are FDA-approved manufactured products with the largest clinical trial evidence base. Both pathways require provider review; the comparison is regulatory and operational, not pharmacologic at the molecule level.

Microdose GLP-1 starts below the standard label entry dose and ramps slowly, prioritizing GI tolerability, muscle preservation, and metabolic adaptation over speed of weight loss. Standard titration follows the manufacturer's label ramp. Both require provider oversight; the choice is candidacy-driven, not preference-driven.

Finasteride blocks 5-alpha reductase, reducing scalp DHT — the upstream driver of androgenetic alopecia. Minoxidil is a vasodilator that prolongs the anagen (growth) phase. They address different mechanisms and are most commonly used together. Topical formulations reduce systemic exposure relative to oral.

Cypionate and enanthate are long-acting injectable testosterone esters with nearly identical pharmacokinetics. Both are standard in provider-reviewed testosterone optimization; the choice is usually driven by formulary availability and patient response, not a meaningful clinical hierarchy.

Cypionate is a long-acting ester used as the modern default in testosterone optimization. Propionate is short-acting and rarely used in contemporary provider-reviewed care because daily-to-alternate-day injections are required to maintain stable physiology.

Topical testosterone is a non-injectable option in provider-reviewed testosterone optimization. Compounded cream and commercial gel deliver testosterone transdermally with different vehicle, concentration, and transfer-risk profiles.

Estradiol is the bioidentical estrogen used in modern BHRT, available transdermally and orally. Conjugated equine estrogens (CEE) are a mixture of equine-derived estrogens historically used in synthetic HRT. Contemporary provider-reviewed care favors bioidentical transdermal estradiol where clinically appropriate.

Micronized progesterone is bioidentical to endogenous progesterone and is the modern default for endometrial protection in BHRT. Synthetic progestins (e.g. medroxyprogesterone) are structurally distinct molecules with different receptor and breast-tissue signaling.

Micronized progesterone is bioidentical; MPA is a synthetic progestin used in legacy HRT regimens. Modern BHRT favors micronized progesterone for endometrial protection due to a more favorable safety and quality-of-life signal.

Sildenafil and vardenafil are short-acting PDE5 inhibitors used for erectile dysfunction. Both have a ~4–6 hour window of effect; vardenafil has slightly higher PDE5 selectivity but the clinical difference is modest. Tadalafil is the modern default for most candidates due to a longer window.

Tadalafil is a long-acting PDE5 inhibitor (~36 hour window) available as on-demand or daily-low-dose therapy. Vardenafil is a short-acting PDE5 inhibitor (~4–6 hour window). Tadalafil is the modern default for most ED candidates due to spontaneity and daily-dosing flexibility.

Semaglutide and liraglutide are both GLP-1 receptor agonists used in metabolic optimization. Semaglutide is weekly and demonstrates greater average weight loss; liraglutide is daily and is largely legacy in contemporary practice.

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist used in metabolic optimization. Retatrutide is an investigational triple-agonist (GIP/GLP-1/glucagon) with promising Phase 2 data but is not yet FDA-approved for clinical use.

Finasteride and dutasteride are 5α-reductase inhibitors that reduce DHT. Finasteride inhibits type II 5α-reductase; dutasteride inhibits both type I and II, producing more profound DHT suppression. Finasteride is the modern default for androgenetic alopecia; dutasteride is reserved for select cases.

Enclomiphene and hCG both support endogenous testosterone and fertility, but through different mechanisms. Enclomiphene acts at the hypothalamus to raise LH/FSH; hCG mimics LH directly at the testes. Both are provider-reviewed for fertility-preserving optimization, with different candidacy.

Sermorelin and ipamorelin are growth hormone secretagogues that stimulate endogenous GH release. Sermorelin is a GHRH analog with a recognized clinical history. Ipamorelin is a GH-releasing peptide with a cleaner side-effect signal and is often combined with CJC-1295 in compounded peptide therapy.

NAD+ is delivered parenterally (IV or subcutaneous) to elevate intracellular NAD+ directly. NMN is an oral precursor that the body converts toward NAD+. Parenteral NAD+ produces higher and more predictable systemic exposure; NMN is convenient but has a less consistent evidence base.

Ozempic is the FDA-approved branded semaglutide pen for type 2 diabetes (commonly used off-label for weight). Compounded semaglutide is prepared by a 503A/503B pharmacy when branded supply is constrained or a customized dose is provider-reviewed.

Wegovy is the FDA-approved branded semaglutide pen labeled for chronic weight management. Compounded semaglutide is prepared by a licensed pharmacy for provider-reviewed metabolic optimization when supply, cost, or titration flexibility require it.

Mounjaro is the FDA-approved branded tirzepatide pen for type 2 diabetes. Compounded tirzepatide is prepared by a licensed pharmacy under provider review for metabolic optimization when supply or titration requires it.

Zepbound is FDA-approved tirzepatide labeled for chronic weight management. Compounded tirzepatide supports metabolic optimization where provider-tuned titration or supply continuity is clinically preferred.

Cialis is the original branded tadalafil; multiple AB-rated generics are available with demonstrated bioequivalence. Generic tadalafil is the standard prescribed in the oMeds sexual-wellness pathway.

Viagra is the original branded sildenafil; multiple AB-rated generics are widely available. Generic sildenafil is the standard cost-effective on-demand PDE5 option, with tadalafil often preferred where a longer window is desired.

Propecia is the original branded finasteride for androgenetic alopecia; multiple AB-rated generics are widely available. Generic finasteride is the standard cost-effective oral option under provider review; topical formulations exist as a lower-systemic-exposure alternative.

Estrace is a branded oral estradiol; multiple AB-rated generics exist. Both deliver bioidentical estradiol, though contemporary BHRT often favors transdermal estradiol regardless of brand-vs-generic.

Depo-Testosterone is a branded injectable testosterone cypionate. Generic cypionate is the standard preparation in modern TRT pathways. Clinical outcomes are equivalent at equivalent doses.

AndroGel is a branded transdermal testosterone gel; AB-rated generic gels are widely available. Both deliver the same active molecule with comparable absorption and transfer-precaution profile.

Subcutaneous and intramuscular injection are both standard delivery routes for testosterone cypionate or enanthate in provider-reviewed testosterone optimization. SubQ has become the modern default for many candidates due to comfort and stable trough behavior; IM remains a long-standing option.

Semaglutide is FDA-labeled for subcutaneous administration in branded and compounded formulations. Intramuscular administration is off-label and not the standard route in provider-reviewed metabolic optimization.

Transdermal estradiol — gel or patch — is the modern default in BHRT because it bypasses first-pass hepatic metabolism. Gel offers dose flexibility per pump; patch offers continuous delivery with twice-weekly application.

Testosterone pellets are subcutaneously implanted depots that release testosterone over months. Compounded cream is a daily topical with provider-tuned concentration. The two routes differ in titration agility, biomarker stability, and reversibility.

Nasal testosterone (Natesto) is a short-acting intranasal gel applied three times daily. Injectable testosterone (cypionate or enanthate) is the long-acting standard in modern TRT. The two differ in cadence, fertility impact, and biomarker stability.

With long-acting esters (cypionate or enanthate), weekly and twice-weekly cadence are both clinically valid. Twice-weekly is the modern default for most candidates because it produces a more stable trough, smoother estradiol behavior, and steadier subjective signal.

Compounded semaglutide is delivered from a vial via insulin-style syringe, enabling fine-titration. Branded pen semaglutide (Ozempic, Wegovy) delivers fixed-step doses. The choice is driven by titration agility, supply, and cost under provider review.

Oral tadalafil is the standard FDA-approved tablet absorbed via the GI tract. The compounded sublingual troche aims for faster onset through buccal absorption. Evidence for meaningfully faster onset is limited; the tablet remains the modern default.

TRT alone suppresses the HPG axis, reducing endogenous testosterone production and testicular volume. Adding hCG preserves intratesticular testosterone signaling, testicular volume, and a fertility window. Selection is provider-reviewed against fertility goals, cost, and biomarker response.

Adding anastrozole to TRT lowers estradiol but is over-prescribed historically. Modern practice prefers TRT alone with careful dosing and cadence, reserving aromatase inhibitors for biomarker-confirmed symptomatic hyperestrogenemia.

Estrogen-only HRT is appropriate after hysterectomy. With an intact uterus, progesterone is required for endometrial protection. Selection is dictated by uterine status, not preference.

Cyclic dosing mimics the natural luteal phase and produces predictable bleeding — preferred in perimenopause. Continuous dosing produces amenorrhea over time and is preferred in postmenopause.

Systemic estrogen addresses vasomotor, sleep, mood, bone, and cardiovascular symptoms. Vaginal estrogen addresses local genitourinary symptoms with minimal systemic absorption. They are often combined.

Adding low-dose testosterone to BHRT is provider-reviewed when libido, energy, or body composition fail to respond to optimized estrogen and progesterone. It is not first-line, and is dosed at female-physiologic levels.

Fast titration reaches therapeutic doses sooner but risks GI intolerance and dropout. Slow, provider-tuned titration improves tolerability and long-term adherence. Compounded vial-based dosing enables fine titration not possible with fixed-step pens.

GLP-1 therapy produces 12–20% mean weight loss; lifestyle-only typically produces 3–8%. Lifestyle remains the foundation under both pathways, and combined therapy is the most durable provider-reviewed approach.

Bariatric surgery produces larger and more durable weight loss but is irreversible and surgical. GLP-1 therapy is reversible, non-surgical, and now closes much of the historical gap, especially with tirzepatide-class molecules.

TRT suppresses endogenous testosterone production and spermatogenesis. Clomiphene (and the enclomiphene isomer) stimulates the HPG axis, raising endogenous testosterone while preserving fertility — making it the fertility-preferred pathway.

Stacks combine peptides with complementary actions (e.g., GHRH + GHRP) to amplify physiologic GH pulse. Single-peptide protocols isolate variables for cleaner attribution. Selection is provider-reviewed against goal, monitoring capacity, and tolerability.

Both are GHRH analogs. Tesamorelin has stronger evidence for visceral adipose reduction and is FDA-approved for HIV-associated lipodystrophy. Sermorelin is shorter-acting, less expensive, and the more common general-wellness peptide.

CJC-1295 (GHRH analog) plus ipamorelin (selective GHRP) produces synergistic GH pulse with minimal cortisol or prolactin impact. Sermorelin is a simpler single-peptide GHRH analog. The stack is the modern default for sustained GH protocols.

BPC-157 supports GI, tendon, and ligament repair. TB-500 supports muscle, broader connective tissue, and vascular repair. They are often used in combined protocols under provider review.

DIM is a cruciferous-derived metabolite that shifts estrogen metabolism toward favorable 2-hydroxy pathways. Anastrozole is a pharmaceutical aromatase inhibitor. DIM is gentler; anastrozole is potent and reserved for confirmed hyperestrogenemia.

LDN (1.5–4.5 mg) is used for autoimmune modulation, chronic pain, and inflammation via transient opioid-receptor blockade and endorphin rebound. Standard 50 mg dosing is for opioid and alcohol use disorder. Indications are entirely distinct.

Both activate AMPK and improve glucose control. Metformin has decades of evidence and is prescription. Berberine is over-the-counter with shorter half-life and similar magnitude in head-to-head trials on glycemic markers, but weaker long-term outcome data.

Statins reduce LDL/ApoB by 30–55% and remain first-line. PCSK9 inhibitors reduce LDL by an additional 50–60% on top of statin and are reserved for high-risk candidates not at goal on maximum-tolerated statin.

Levothyroxine alone is the modern default. A subset of candidates with persistent symptoms despite normalized TSH benefit from T4 + T3 combination therapy. Selection is provider-reviewed against free T3, reverse T3, and symptom profile.

Levothyroxine is precisely standardized synthetic T4 and the modern default. Desiccated thyroid is porcine-derived T4 + T3 at a fixed ratio favoring T3. A subset of candidates prefer NDT for symptom control, accepting batch variability.

Annual cadence is appropriate for steady-state wellness monitoring. Quarterly cadence is the provider-reviewed default during active optimization (initiation, dose changes, hormone titration) and for high-variability biomarkers.

The 4-panel (Hormones, Lipids, CBC, CMP) is the oMeds default standardized read across pathways. The comprehensive panel adds advanced lipoproteins, inflammation, micronutrients, and methylation markers. Selection is goal-driven.

Provider-reviewed optimization is anchored to a standardized biomarker panel, licensed provider review in the candidate's state, and longitudinal continuity. Self-directed protocols lack panel discipline, licensing, and safety adjudication. oMeds operates exclusively as the provider-reviewed pathway.

Lifestyle (sleep, resistance training, body composition, alcohol reduction) can raise testosterone 50–150 ng/dL in most candidates. TRT is the provider-reviewed pathway when biomarkers and symptoms confirm deficiency that lifestyle alone cannot bridge.

Synchronous live video with a licensed provider in the candidate's state is the oMeds standard for every optimization pathway. Asynchronous review compresses clinical depth and is not used at oMeds.

Long-acting esters support weekly or twice-weekly cadence and are the modern TRT default. Short-acting propionate requires every-other-day injection and is niche — used for finer trough control or rapid washout scenarios.

Tirzepatide produces 18–22% mean weight loss — narrower than the historical gap between GLP-1 monotherapy and bariatric surgery. Surgery remains more durable, but tirzepatide is now a credible non-surgical alternative for many candidates.

NAD+ IV delivers direct, high-magnitude tissue replenishment on a periodic cadence. Oral NMN raises NAD+ precursor levels daily at lower magnitude with better convenience. The two are complementary in modern longevity protocols.

Total testosterone measures all circulating testosterone — bound and unbound. Free testosterone reflects the unbound, bioactive fraction. Symptoms often track free testosterone more closely, but interpretation depends on SHBG, albumin, and assay method. Both are read together on the standardized hormone panel.

ApoB counts every atherogenic particle (LDL, VLDL, IDL, Lp(a)). LDL-C estimates cholesterol mass inside LDL particles. When the two diverge — common in metabolic syndrome and insulin resistance — ApoB is the more accurate cardiovascular risk marker.

LDL-P measures the count of LDL particles via NMR. LDL-C measures the cholesterol carried inside those particles. Like ApoB vs LDL-C, particle count outperforms cholesterol mass when the two diverge — particularly in metabolic syndrome.

HbA1c reflects average glucose over ~3 months via hemoglobin glycation. Fasting glucose is a single-morning snapshot. The two diverge in anemia, hemoglobinopathy, and rapid metabolic change — both are read together with fasting insulin for an accurate picture.

HbA1c gives a single average over ~3 months. CGM exposes glucose variability, post-prandial spikes, and overnight dips. For metabolic optimization, CGM reveals patterns HbA1c cannot — but HbA1c remains the standardized trend marker for the panel.

Fasting insulin is a direct measure. HOMA-IR combines fasting insulin and fasting glucose into a single insulin-resistance index. HOMA-IR is more sensitive for early insulin resistance than either marker alone.

TSH alone is the screening standard but misses central hypothyroidism, conversion defects, and autoimmune thyroiditis. A full panel (TSH, Free T4, Free T3, Reverse T3, TPO/Tg antibodies) is required when symptoms persist despite a normal TSH.

Free T3 is the active thyroid hormone. Reverse T3 is the inactive isomer produced during stress, illness, or caloric restriction. The Free T3 / Reverse T3 ratio reveals conversion quality and is decisive when TSH and Free T4 look normal but symptoms persist.

Standard CRP detects acute, large-magnitude inflammation. hs-CRP detects the low-grade chronic inflammation that drives cardiovascular and metabolic disease. For optimization, hs-CRP is the relevant marker.

SHBG is the carrier protein that binds testosterone. FAI is the ratio of total testosterone to SHBG, expressed as a percentage. Together they explain why two patients with identical total testosterone can have very different bioactive testosterone.

DHEA-S reflects chronic, slow-pool adrenal output. AM cortisol reflects acute, diurnal-peak adrenal output. The cortisol-to-DHEA ratio captures stress-axis imbalance better than either alone.

Omega-3 Index measures EPA + DHA as a percentage of RBC membrane fatty acids — a direct nutritional status marker. The standard lipid panel measures cholesterol fractions. They answer different questions and are read together for cardiovascular optimization.

At-home panels deliver high adherence and convenience for the standardized panel (Hormones, Lipids, CBC, CMP). In-lab draws cover specialty assays requiring serum integrity, larger volumes, or refrigerated transport. Both are CLIA-grade when performed correctly.

DEXA is the clinical gold standard for body composition — directly measures bone, lean mass, and fat by region. BIA estimates the same via electrical conductance and is sensitive to hydration. DEXA is decisive for baseline; BIA is appropriate for high-frequency trend.

VO2 max measures peak oxygen uptake — the most validated longevity marker. RMR measures baseline caloric burn at rest — the foundation for metabolic and weight pathway calibration. They are complementary, not interchangeable.

TRT directly replaces testosterone. Peptide pathways (e.g., growth hormone secretagogues, healing peptides) work upstream on endogenous axes. They are not substitutes — they answer different optimization questions and frequently coexist in stacked pathways.

BHRT addresses the underlying hormonal driver of perimenopausal and menopausal symptoms. Symptom-only management (SSRIs, gabapentin, lifestyle, cooling) treats the manifestation without altering the underlying hormone trajectory. Choice depends on candidacy, contraindications, and patient preference.

Semaglutide drives appetite, satiety, and glucose-axis change — producing significant weight loss in candidates. Lipo-B is a lipotropic and B-vitamin support protocol — metabolic and energy support, not a weight-loss therapy. They occupy different roles and frequently stack.

NAD+ pathways restore cellular cofactor levels driving mitochondrial function and sirtuin activity. Peptide longevity pathways stimulate endogenous axes (growth hormone, healing, immune). They operate on different biology and are complementary in modern longevity protocols.

Hormone replacement (TRT/BHRT) and peptide pathways are not mutually exclusive — candidacy depends on biomarkers, fertility goals, age, and symptom profile. This decision-support comparison maps the routing logic used in provider review.